Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

C David Mazer; Gregory M T Hare; Philip W Connelly; Richard E Gilbert; Nadine Shehata; Adrian Quan; Hwee Teoh; Lawrence A Leiter; Bernard Zinman; Peter Jüni; Fei Zuo; Nikhil Mistry; Kevin E Thorpe; Ronald M Goldenberg; Andrew T Yan; Kim A Connelly; Subodh Verma

doi:10.1161/CIRCULATIONAHA.119.044235

Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Circulation. 2020 Feb 25;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235. Epub 2019 Nov 11.

Authors

C David Mazer^{1

2

3

4

5}, Gregory M T Hare^{1

2

3

4

5}, Philip W Connelly^{2

6

7}, Richard E Gilbert^{8

2

3

6}, Nadine Shehata^{6

7

9

10}, Adrian Quan^{11

2

3}, Hwee Teoh^{8

11

2

3}, Lawrence A Leiter^{8

3

6

12}, Bernard Zinman^{6

13}, Peter Jüni^{14

3

6

9}, Fei Zuo^{14

3}, Nikhil Mistry^{1

3}, Kevin E Thorpe^{14

3

15}, Ronald M Goldenberg¹⁶, Andrew T Yan^{17

3

6}, Kim A Connelly^{17

2

3

5

6}, Subodh Verma^{11

2

3

18

19}

Affiliations

¹ Department of Anesthesia (C.D.M., G.M.T.H., N.M.), Unity Health Toronto, Ontario, Canada.
² Keenan Research Centre for Biomedical Science (C.D.M., G.M.T.H., P.W.C., R.E.G., A.Q., H.T., K.A.C., S.V.), Unity Health Toronto, Ontario, Canada.
³ Li Ka Shing Knowledge Institute of St Michael's Hospital (C.D.M., G.M.T.H., R.E.G., A.Q., H.T., L.A.L., P.J., F.Z., N.M., K.E.T., A.T.Y., K.A.C., S.V.), Unity Health Toronto, Ontario, Canada.
⁴ Department of Anesthesia (C.D.M., G.M.T.H.), University of Toronto, Ontario, Canada.
⁵ Department of Physiology (C.D.M., G.M.T.H., K.A.C.), University of Toronto, Ontario, Canada.
⁶ Department of Medicine (P.W.C., R.E.G., N.S., L.A.L., B.Z., P.J., A.T.Y., K.A.C.), University of Toronto, Ontario, Canada.
⁷ Department of Laboratory Medicine and Pathobiology (P.W.C., N.S.), University of Toronto, Ontario, Canada.
⁸ Division of Endocrinology and Metabolism (R.E.G., H.T., L.A.L.), Unity Health Toronto, Ontario, Canada.
⁹ Institute of Health Policy, Management and Evaluation (N.S., P.J.), University of Toronto, Ontario, Canada.
¹⁰ Division of Hematology (N.S.), Toronto, Ontario, Canada.
¹¹ Division of Cardiac Surgery (A.Q., H.T., S.V.), Unity Health Toronto, Ontario, Canada.
¹² Department of Nutritional Sciences (L.A.L.), University of Toronto, Ontario, Canada.
¹³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital (B.Z.), Toronto, Ontario, Canada.
¹⁴ Applied Health Research Centre (P.J., F.Z., K.E.T.), Unity Health Toronto, Ontario, Canada.
¹⁵ and Dalla Lana School of Public Health (K.E.T.), University of Toronto, Ontario, Canada.
¹⁶ LMC Diabetes & Endocrinology, Concord, Ontario, Canada (R.M.G.).
¹⁷ Division of Cardiology (A.T.Y., K.A.C.), Unity Health Toronto, Ontario, Canada.
¹⁸ Department of Surgery (S.V.), University of Toronto, Ontario, Canada.
¹⁹ Department of Pharmacology and Toxicology (S.V.), University of Toronto, Ontario, Canada.

PMID: 31707794
DOI: 10.1161/CIRCULATIONAHA.119.044235

No abstract available

Keywords: empagliflozin; erythrocytes; erythropoietin; iron; sodium-glucose transporter 2 inhibitors.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzhydryl Compounds / therapeutic use*
Coronary Artery Disease / complications*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Erythrocyte Count
Erythrocytes / cytology
Erythrocytes / drug effects
Erythrocytes / pathology*
Erythropoietin / analysis*
Ferritins / metabolism
Glucosides / therapeutic use*
Hematocrit
Humans
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
Erythropoietin
Ferritins
empagliflozin